source
- Merck touts promising ADC sacituzumab tirumotecan as potential cornerstone therapy at ASCOMerck highlighted a new antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), licensed from Chinese biotech Kelun-Biotech, at the ASCO meeting. The company said early clinical data have give…
- White House reviews FDA's new prescription drug user fee agreement for 2028-2032The White House is currently reviewing a recently negotiated agreement between the FDA and the biopharma industry that determines the level of prescription-drug user fees for the period 2028 throug…